Elanco Q2 revenue up 10% to $1.37B; raises full-year guidance on innovation momentum

Elanco Animal Health Inc

Q2 revenue $1,368M (+10% YoY); organic constant currency growth 8%.
Adjusted EPS $0.34 (+31% YoY); reported EPS $0.11 vs $0.02.
Full-year 2026 guidance raised: revenue $5.09B-$5.14B, Adj EBITDA $1.01B-$1.035B, Adj EPS $1.10-$1.16.
Innovation revenue target raised to $1.25B; net leverage ratio improved to 3.1x, targeting ~3.0x year-end.
Pet Health revenue +12% driven by Zenrelia and Credelio Quattro; Farm Animal +9%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.